List of Excipients in API letermovir
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing letermovir
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | PREVYMIS | letermovir | 0006-3075 | CARNAUBA WAX | 2031-08-30 |
| Merck Sharp & Dohme LLC | PREVYMIS | letermovir | 0006-3075 | CELLULOSE, MICROCRYSTALLINE | 2031-08-30 |
| Merck Sharp & Dohme LLC | PREVYMIS | letermovir | 0006-3075 | CROSCARMELLOSE SODIUM | 2031-08-30 |
| Merck Sharp & Dohme LLC | PREVYMIS | letermovir | 0006-3075 | FERRIC OXIDE YELLOW | 2031-08-30 |
| Merck Sharp & Dohme LLC | PREVYMIS | letermovir | 0006-3075 | HYPROMELLOSE 2910 | 2031-08-30 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for letermovir
Excipient focus: CARNAUBA WAX
letermovir drug variants containing CARNAUBA WAX
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing CARNAUBA WAX
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
letermovir drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
letermovir drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
letermovir drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
letermovir drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
letermovir drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
letermovir drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K25
letermovir drug variants containing POVIDONE K25
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing POVIDONE K25
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
letermovir drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
letermovir drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
letermovir drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | letermovir | 0006-3075 |
| >Company | >Ingredient | >NDC |
letermovir drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch